Wednesday, January 7, 2009

Breaking: FDA extends review date for Reloxin

Reuters is reporting that the FDA has extended the initial review of Ipsen's botulinum Type A toxin product, Reloxin, anticipated as the first American competitor to Botox.

According to Ipsen, the FDA also confirmed that their Wales facility for manufacturing the product is in compliance with their regulations.

Dr. David Goldberg
Sanctuary Medical Aesthetic Center
Skin Laser Surgery Specialists of NY/NJ

No comments:

Post a Comment